Mutations in the IDH2 gene have been identified in various cancers, including acute myeloid leukemia (AML), cholangiocarcinoma, and gliomas. These mutations often result in the production of an abnormal enzyme that converts alpha-ketoglutarate into an oncometabolite called 2-hydroxyglutarate (2-HG). The accumulation of 2-HG disrupts normal cellular processes and promotes tumorigenesis.
